法布里心肌病心脏植入式电子装置植入指征与使用研究
结果显示永久起搏器植入者92%符合1类指征,而ICD植入者仅28%符合,另有44%超出现行指南进行一级预防;装置组心律失常负担高,且年龄更大、LV质量更高、瘢痕更多、左房更大。结论支持法布里病特异性装置植入指征的必要性。
要点
- 法布里病患者心律失常常见,装置组房颤需抗凝及室性心律失常需装置治疗的比例高。
- 永久起搏器植入者92%符合1类指征,但ICD植入者仅28%符合,44%超指南一级预防。
- 装置组患者年龄更大、LV质量更高、瘢痕更多、左房更大,提示疾病进展与装置需求相关。
核心结论
- 法布里病患者心律失常负担高,装置植入率与指征符合度存在差异,支持制定法布里病特异性装置植入指征。
主要发现
- FD-CIED组中永久起搏器植入者92%符合1类指征,ICD植入者仅28%符合1类指征。
- FD-CIED组中44%的ICD植入为超出现行指南的一级预防。
- FD-CIED组心律失常负担高:无症状房颤29%,需药物治疗的非持续性室速26%,需抗心动过速起搏/除颤的持续性室速28%。
- 装置组患者年龄更大、LV质量更高、瘢痕组织更多、左房尺寸更大。
关键数值与推荐
- 永久起搏器1类指征符合率92%,ICD1类指征符合率28%,超指南一级预防ICD植入占44%。
临床怎么用
- 临床中应关注法布里病患者心律失常筛查,装置植入决策需结合指征符合度与疾病进展标志(LV质量、瘢痕、左房大小)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fabry disease is a treatable X-linked condition leading to progressive cardiomyopathy, arrhythmia and premature death. Atrial and ventricular arrhythmias contribute significantly to adverse prognosis; however, guidance to determine which patients require cardiovascular implantable electronic devices (CIEDs) is sparse. We aimed to evaluate indications for implantation practice in the UK and quantify device utilisation. METHODS: In this retrospective study, we included demographic, clinical and imaging data from patients in four of the largest UK Fabry centres. Ninety patients with Fabry disease were identified with CIEDs implanted between June 2001 and February 2018 (FD-CIED group). To investigate differences in clinical and imaging markers between those with and without devices, these patients were compared with 276 patients without a CIED (FD-control). RESULTS: In the FD-CIED group, 92% of patients with permanent pacemakers but only 28% with implantable cardioverter-defibrillators had a class 1 indication for implantation. A further 44% of patients had defibrillators inserted for primary prevention outside of current guidance. The burden of arrhythmia requiring treatment in the FD-CIED group was high (asymptomatic atrial fibrillation:29%; non-sustained ventricular tachycardia requiring medical therapy alone: 26%; sustained ventricular tachycardia needing anti-tachycardia pacing/defibrillation: 28%). Those with devices were older, had greater LV mass, more scar tissue and larger atrial size. CONCLUSIONS: Arrhythmias are common in Fabry patients. Those with cardiac devices had high rates of atrial fibrillation requiring anticoagulation and ventricular arrhythmia needing device treatment. These are as high as those in hypertrophic cardiomyopathy, supporting the need for Fabry-specific indications for device implantation.
引用
- Vijapurapu R, Geberhiwot T, Jovanovic A, et al. Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy. Heart. 2019. PMID: 31446426. doi:10.1136/heartjnl-2019-315229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。